CARGO Therapeutics, Inc. Common Stock CRGX Open CARGO Therapeutics, Inc. Common Stock in new tab
CARGO Therapeutics, Inc. Common Stock Analysis (CRGX)
Is CARGO Therapeutics, Inc. Common Stock a good investment? CARGO Therapeutics, Inc. Common Stock (CRGX) is currently trading at 4.47 USD.
Earnings Schedule: CARGO Therapeutics, Inc. Common Stock is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is -4.66.
Investor FAQ
Does CARGO Therapeutics, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is CARGO Therapeutics, Inc. Common Stock?
CARGO Therapeutics, Inc. Common Stock is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of -4.62.
Company Profile
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively limit immune-based rejection to enable durable response of CAR T-cell therapy. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is based in San Carlos, California. As of August 18, 2025, CARGO Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion